BioCentury | Jun 23, 2020
Distillery Therapeutics

Blocking cGAS signaling for alcohol-related liver disease

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the gap junction protein GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 19, 2020
Product Development

T cell tests aim for broader picture of COVID-19 immunity

While the COVID-19 testing conversation has centered on assays for antiviral antibodies or the virus itself, at least two companies think T cell tests could catch patients the other methods miss. T cell tests could...
BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection by preventing HA-mediated viral entry. The nanoparticles comprise icosahedral bacteriophage capsid proteins conjugated to mono-ethylene glycol-linked sialic acid, which...
BioCentury | May 9, 2020
Product Development

REMAP-CAP master protocol has lessons for studying drug cocktails

The U.K.’s REMAP-CAP master protocol is poised to teach drug developers a way to cut through the mess of individual trials for drug combos in diseases where drug cocktails are all but inevitable. If successful,...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

Valneva gets $130M up front in Lyme disease vaccine deal  Pfizer Inc. (NYSE:PFE) will collaborate with Valneva SE (Euronext:VLA) to develop VLA15, the biotech’s vaccine candidate for Lyme disease. In a deal announced Thursday, Valneva...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 16, 2020
Translation in Brief

SARS-CoV-2 fluorescent tool for drug development; plus Alzheimer's biomarkers, Nature, National Academies and Pylum

DNA-based tool for developing COVID-19 countermeasures University of Texas Medical Branch researchers have created a fluorescent SARS-CoV-2 DNA clone as a reporter tool for preclinically assessing COVID-19 vaccines and treatments. Described in Cell Host and...
BioCentury | Apr 15, 2020
Politics, Policy & Law

WHO names former GSK CEO Witty to co-lead COVID-19 vaccine after Trump cuts U.S. funding

Andrew Witty will take a leave of absence from his roles as president of UnitedHealth and CEO of the group’s Optum health services unit to co-lead WHO’s program to accelerate the development of COVID-19 vaccines....
Items per page:
1 - 10 of 4002